study does not qualify as scienti®c evidence supporting anticoagulant treatment to reduce the morbidity and/or mortality of patients with PE. Therefore, we cannot extrapolate the conclusion of Barritt and Jordan's trial to DVT patients or further extrapolate it to super®cial venous thrombosis patients.
More recently in patients with DVT, Nielsen et al. compared heparin plus phenprocoumon anticoagulation with phenylbutazone in the only published randomized controlled trial 3, 4 . It was a negative study with 1/48 anticoagulated patients and 0/42 phenylbutazone patients dying of pulmonary embolism.
For the articles and FDA correspondence detailing the case for withdrawing the indications for anticoagulants (heparins and vitamin K antagonists) in prophylaxis and treatment of venous thromboembolism, see my website: Selenium is an essential component of glutathione peroxidase (GPX) 5 , and this enzyme together with catalase, superoxide dismutase, and vitamin E provides a line of defence against pro-oxidant molecules. In the absence of selenium, GPX is inactive and low GPX is found in HIV disease 5 . GPX activity increases after selenium supplementation 5 . Also the oxidative muscle damage produced by zidovudine treatment can be prevented with anti-oxidants 6 .
TPN is increasingly being used in HIV and other chronic illness. Adequate supplementation of selenium in TPN and in malnourished patients might protect against the development of cardiomyopathy in these patients. To date, there are no of®cial guidelines regarding the use of selenium in TPN. Otorhinolaryngologists also encounter such injuries. We presented a series of three cases previously 1 ; since then two more have been seen. Included in the series was a 14-year-old boy who, whilst walking with a friend along one of the canals in West Bromwich, Birmingham, felt a sudden sharp pain in the left eye. At the time, he was unaware that he had been shot. On arrival at home his father noticed bleeding from his left eye. He was taken to Sandwell District Hospital and a pellet was shown lodged in the right sphenoid sinus. The eye was damaged and had to be removed. The pellet was extracted from the sphenoid sinus. The path of the pellet was through the left eye, left ethmoid sinuses, through the cartilagenous nasal septum (creating a permanent hole) and nose. The pellet ricocheted off the right lateral wall of the nose and lodged in the right sphenoid sinus having entered the sinus through its anterior wall. The perpetrator of this injury was found to be a 9-yearold boy playing unsupervised with an airgun. We agree with Shuttleworth and Galloway that more measures need to be taken to avoid such injuries, but we think the best way is through raising public awareness.
Syed Wamique Yusuf
Another important point to discuss is: remove or leave the pellet? A further case dealt with since this report was of a patient who had had a pellet lodged in her face (on the anterior surface of the maxillary sinus) for well over 30 years. When she was a child whilst walking with her elder sister in a park in West Bromwich, she felt a sudden sharp pain in her cheek. Blood was found tracking from a small wound on the cheek and nothing much was done about this at the time. After more than 30 years there was a reunion between the two sisters attending their mum's funeral, and the younger sister was prompted to seek advice. An X-ray showed a pellet lying on the anterior surface of the maxillary sinus. Blood lead concentration was not raised. Personally, I favour removal of lodged pellets, and this was done. 
Ahmes L Pahor
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